<DOC>
	<DOC>NCT03023202</DOC>
	<brief_summary>This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.</brief_summary>
	<brief_title>UWCCC Molecular Tumor Board Registry</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Clinically suspected or histologically confirmed solid or hematological malignancy Undergoing genetic testing of tumor Ability to understand written informed consent document Willingness to sign written informed consent document Pediatric patients (age&lt;18 years) will be excluded due to a lack of expertise on the molecular tumor committee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>